Half Yearly Report and Accounts
Released
Released
Announcement PDF
26 February 2025
Manager, Company Announcements
ASX Limited
Level 4
20 Bridge Street
SYDNEY NSW 2000
Via E-Lodgement
Dear Sir/Madam
Mayne Pharma Group Limited
Interim Results
Please find attached the Appendix 4D Half Year Report, Directors’ Report, the Financial Report and
Auditor’s Independent Review Report relating to the results for the half-year ended 31 December
2024.
This information should be read in conjunction with Mayne Pharma Group Limited’s 2024 Annual
Report.
This announcement comprises the information required by ASX Listing Rule 4.2A and the statement
required by Rule 4.2C.2.
Yours faithfully,
Mayne Pharma Group Limited
Laura Loftus
Company Secretary
Appendix 4D
Interim Results
Half Year Report
RESULTS FOR ANNOUNCEMENT TO THE MARKET
APPENDIX 4D – HALF YEAR REPORT
% Change
Dec 2024
Dec 2023
$’000
$’000
Revenue from ordinary activities
13%
213,054
187,926
Profit / (loss) from continuing operations before income tax expense
80%
(14,719)
(74,865)
Profit / (loss) from continuing operations after income tax expense
72%
(19,970)
(70,549)
(5,575)
(3)
(25,545)
(70,552)
(25,545)
(70,552)
Other comprehensive income after income tax expense
15,604
(7,382)
Total comprehensive income after income tax expense
(9,941)
(77,934)
Equity holders of the parent
(9,941)
(77,934)
Net tangible assets per ordinary share (1)
($1.69)
($0.47)
2024
$
2023
$
Profit / (loss) from discontinued activities after income tax
Profit / (loss) after income tax
64%
Attributable to:
Equity holders of the parent
Attributable to:
Basic earnings per share continuing operations
(0.25)
(0.88)
Diluted earnings per share continuing operations
(0.25)
(0.88)
Final dividend in respect of the financial year ended 30 June per share
Nil
Nil
Interim dividend in respect of the period ended 31 December per share
Nil
Nil
(1)
Net tangible assets include Right-of-use lease assets
Refer to the Directors’ Report and the accompanying ASX announcement dated 26 February 2025 for a brief commentary on the
results.
Page 2
Half Year Financial Report
FOR THE HALF YEAR ENDED 31 DECEMBER 2024
(PRIOR CORRESPONDING PERIOD: HALF YEAR ENDED 31 DECEMBER 2023)3
Appendix 4D
Interim Results
Half Year Report
CONTENTS
CORPORATE INFORMATION ...................................................................................................................................................... 5
DIRECTORS’ REPORT .................................................................................................................................................................. 6
AUDITOR’S INDEPENDENCE DECLARATION ............................................................................................................................. 12
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME ................................................... 13
CONSOLIDATED STATEMENT OF FINANCIAL POSITION ........................................................................................................... 15
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY ............................................................................................................ 16
CONSOLIDATED STATEMENT OF CASH FLOW ......................................................................................................................... 17
NOTES TO THE FINANCIAL STATEMENTS ................................................................................................................................. 18
DIRECTORS’ DECLARATION ...................................................................................................................................................... 40
AUDITOR’S INDEPENDENT REVIEW REPORT ........................................................................................................................... 41
Page 4
Appendix 4D
Interim Results
Half Year Report
CORPORATE INFORMATION
DIRECTORS:
Mr Frank Condella (Chair)
Mr Shawn Patrick O’Brien (Managing Director and CEO)
Mr Patrick Blake
Ms Ann Custin
Mrs Anne Lockwood
Dr Kathryn MacFarlane
Mr David Petrie
Prof Bruce Robinson, AC
COMPANY SECRETARY:
Ms Laura Loftus
REGISTERED OFFICE
1538 Main North Road
Salisbury South
South Australia 5106
PRINCIPAL PLACES OF
BUSINESS:
1538 Main North Road
Salisbury South
South Australia 5106
3301 Benson Drive Suite 401
Raleigh
North Carolina 27609 USA
AUDITORS:
BDO Audit Pty Ltd
Collins Square | Tower Four
Level 18, 727 Collins Street
Melbourne VIC 3008
SOLICITORS:
Minter Ellison Lawyers
Collins Arch
Level 20, 447 Collins Street
Melbourne VIC 3000
SHARE REGISTRY:
Computershare Investor Services Pty Ltd
Yarra Falls
452 Johnston Street
Abbotsford VIC 3067
Telephone:
(03) 9415 4184
Facsimile:
(03) 9473 2500
BANKER:
Westpac
150 Collins Street
Melbourne VIC 3000
ABN:
76 115 832 963
DOMICILE AND COUNTRY
OF INCORPORATION:
Australia
LEGAL FORM OF ENTITY:
Public company listed on the Australian Securities Exchange (MYX)
Page 5
Appendix 4D
Interim Results
Half Year Report
DIRECTORS’ REPORT
The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as
the 'Consolidated Entity') consisting of Mayne Pharma Group Limited (referred to hereafter as the 'Company' or 'parent entity')
and the entities it controlled at the end of, or during, the half-year ended 31 December 2024.
DIRECTORS
The names of the Company’s Directors in office during the half-year and until the date of this report are set out below. Directors
were in office for this entire period unless otherwise noted.
Mr Frank Condella, Chair
Mr Shawn Patrick O’Brien, Managing Director and CEO
Mr Patrick Blake
Ms Ann Custin
Mrs Anne Lockwood
Dr Kathryn MacFarlane
Mr David Petrie
Prof Bruce Robinson, AC
REVIEW OF RESULTS
Mayne Pharma reported revenue for the half year of $213.1m reflecting a strong performance by the Women’s Health segment
(formerly BPD) and the Dermatology segment (formerly PPD).
The Consolidated Entity’s net loss from continuing operations attributable to members of the Company for the half-year ended
31 December 2024 was a loss of $20.0m (half-year ended 31 December 2023: net loss $70.5m).
Set out below is a summary of the financial performance attributable to Mayne Pharma shareholders for the six months ended
31 December 2024. This summary includes non-IFRS financial information that is stated excluding certain non-operating
income and expense items. The results are set out this way as the Directors consider them to be a meaningful comparison from
period to period. Earnings before interest tax, impairment, depreciation and amortisation (EBITDA) is used as a key measure of
the earnings considered by management in operating the business and assessing performance.
DEC 2024
$M
DEC 2023
$M
CHANGE ON PCP
$M
Reported Revenue from continuing operations
213.1
187.9
25.2
Reported Gross profit from continuing operations
130.9
105.8
25.1
Reported Gross profit %
61.4%
56.3%
SALES AND PROFIT
Adjusted EBITDA
31.0
8.0
23.0
Adjustments1
(4.9)
(29.9)
25.0
Reported EBITDA from continuing operations
26.1
(21.9)
48.0
Depreciation / Amortisation
(32.7)
(35.9)
3.2
Reported Profit / (Loss) Before net finance expenses and Tax from continuing operations
(6.6)
(57.8)
51.2
Net interest
0.2
1.8
(1.6)
Foreign exchanges gains/(losses) financing activities
9.3
(3.5)
12.8
Earn-out & deferred consideration liabilities discount unwind
(17.6)
(15.3)
(2.3)
Reported Profit / (Loss) Before Tax from continuing operations
(14.7)
(74.8)
60.1
Income tax credit / (expense)
(5.3)
4.3
(9.6)
Reported Net Profit / (Loss) After Tax attributable to Mayne Pharma shareholders from
continuing operations
(20.0)
(70.5)
50.5
1.
Current year adjustments are included in the table below.
Page 6
Appendix 4D
Interim Results
Half Year Report
The reconciliation of reported results and underlying results from continuing operations is as follows:
REPORTED
ATTRIBUTABLE
EARN-OUT
TO MEMBERS REASSESSMENT RESTRUCTURING
(1)
(2)
DEC 2024
SALES AND PROFIT
$M
$M
$M
LITIGATION(3)
DILIGENCE &
BUSINESS
DEVELPOMENT
EXP(4)
MARK TO
MARKET
REASSESSMENT
DERIVATIVE (5)
$M
$M
$M
CONTINUING
OPERATIONS
UNDERLYING
DEC 2024
$M
Revenue
213.1
213.1
Gross profit
130.9
130.9
Gross profit %
61.4%
61.4%
EBITDA
26.1
Depreciation /
Amortisation
(32.7)
PBIT
(6.6)
Net finance costs
(8.1)
PBT
(14.7)
(1)
(2)
(3)
(4)
(5)
(1.0)
1.2
2.4
2.5
(0.2)
31.0
(1.0)
1.2
2.4
2.5
(0.2)
(1.7)
(1.0)
1.2
2.4
2.5
(0.2)
(9.8)
(32.7)
(8.1)
Earn-out and deferred consideration liabilities reassessment.
Restructuring costs principally related to organisational restructuring.
Drug pricing and health care investigations, US Department of Justice and related litigation costs.
Diligence and business development expenses
Mark to market / fair value reassessment of the conversion derivative relating to convertible notes.
The non IFRS financial information is unaudited. A more detailed analysis of the operating performance is included in the ASX
Announcement and Results Presentation dated 26 February 2025.
REVIEW OF OPERATIONS
The Group’s focus is on extracting operating efficiency leverage and growth from existing assets.
Work on the Salisbury modernisation project, partly funded by a federal government grant, is progressing well. The new
encapsulator entered commercial production at the end of FY24, enabling the launch of KAPANOL® 200mg. Upcoming
installations include a bottling line and a high-speed blister packing line with serialisation capabilities. Site acceptance testing
of these is scheduled to be completed in March 2025, with commercial production scheduled to commence from July 2025.
The Group recorded revenue of $213.1m, up 13% on the prior corresponding period (pcp) and gross profit was $130.9m, up
24% on pcp.
Gross profit reported as a percentage of sales revenue was 61.4% versus 56.3% in the pcp.
The Consolidated Entity operates in three operating segments being International, Women’s Health (formerly BPD) and
Dermatology (formerly PPD). During a prior period, the Consolidated Entity sold the MCS segment and has therefore included
MCS in discontinued operations (refer Note 5). The Consolidated Entity also sold the Retail Generics business effective 7 April
2023 which has also been disclosed as part of discontinued operations (refer Note 5). The segment note in the financial
statements (Note 2) shows the sales, gross margin (GM), direct operating expenses (opex) and the direct contribution (being
the GM less direct opex) for each segment on a continuing operations basis.
Women’s Health
The Women’s Health Division distributes branded Women’s Health products in the US. This division includes NEXTSTELLIS®,
ANNOVERA®, BIJUVA® and IMVEXXY®.
Women’s Health revenue increased 30% to $94.3m ($72.4m pcp) and gross profit increased 31% to $76.9m ($58.7m pcp) for
the period. Direct contribution increased 117% to $39.3m ($18.1m pcp) due to increased operating leverage from the continued
revenue and gross profit growth across the Women’s Health portfolio.
In USD terms, Women’s Health revenue increased 32% to US$62.3m (US$47.3m pcp) and gross profit increased 32% to
US$50.8m (US$38.3m pcp) for the period. Direct contribution increased 120% to US$26.0m (US$11.8m pcp). Key products
driving revenue growth compared to the pcp were NEXTSTELLIS® (increase 62%) and IMVEXXY® (increase 46%). BIJUVA®
revenue increased 31% with ANNOVERA® remaining consistent compared to the pcp. Although ANNOVERA® revenue remains
Page 7
Appendix 4D
Interim Results
Half Year Report
flat versus the pcp due to the lingering effects of legacy inventory returns, total prescription (‘TRx’) volumes are up 14% in that
same time-period. Market share for the brand represents ~1% of their direct competitive set, providing opportunity for
continued growth. The direct contribution growth is driven by increased revenues and continued optimization of operating
leverage.
Dermatology
The Dermatology Division distributes established dermatology products in the US.
Revenue increased 1% to $81.4m ($80.9m pcp), gross profit increased 19% to $43.4m ($36.6m pcp) and direct contribution
increased 22% to $22.1m ($18.1m pcp) for the period.
In USD terms, revenue increased 2% to US$53.8m (US$52.9m pcp), gross profit increased 20% to US$28.7m (US$23.9m pcp)
and direct contribution increased 23% to a US$14.6m (US$11.8m pcp) for the period.
Dermatology net revenues compared to the pcp nominally increased and include a lift in RHOFADE® and a decline in AG
ORACEA® – the net of these two stand-alone totalling minus 4%. Dermatology revenues experienced significant seasonality 1H
FY25 vs 2H FY24. Dermatology contribution increases are driven by the mix of products and by some effects of the Company’s
channel management (disintermediation).
International
International’s revenue and gross profit are derived from the Australian manufacture and sale of branded and generic
pharmaceutical products globally and the provision of contract development and manufacturing services to third party
customers.
International revenue increased 8% to $37.4m ($34.6m pcp), gross profit increased by 1% to $10.6m ($10.5m pcp) and direct
contribution decreased 18% to $3.6m ($4.4m pcp) for the period.
International performance was impacted by timing of certain shipments and production schedules. International’s delivery in
full on time (DIFOT) for 1H FY25 has improved to 91% compared to 76% in the pcp.
Expenses
Net research, development, medical and regulatory affairs expense (total costs less costs capitalised) was $9.9m, a decrease in
expense of $0.4m on the pcp.
Marketing and distribution expenses were $66.0m, a net increase of $1.0m on the pcp. The increase includes additional
investment in the Dermatology distribution channel.
Administration and other expenses were $63.9m, a decrease of $8.7m on the pcp. This category includes non-cash and / or
non-operating items such as:
•
•
•
•
•
•
•
Amortisation of intangible assets $28.5m ($31.5m pcp);
Reassessment of derivative fair value $0.2m credit ($10.0m expense pcp);
Share based payments expense $2.1m ($2.5m pcp);
Foreign exchange losses $1.0m ($0.9m fx gain pcp);
Restructuring expenses $1.2m ($0.4m pcp);
Diligence and business development expenses $2.5m (nil pcp); and
Litigation costs $2.4m ($2.8m pcp).
Amortisation expense includes $8.3m (pcp $12.8m) for NEXTSTELLIS® and $14.7m (pcp $14.9m) for the TXMD assets. The
balance of amortisation relates to Dermatology and International intangibles.
Excluding the non-cash and / or non-operating items, administration and other expenses increased by $0.1m to $26.4m.
There were no asset impairments in the current period or the pcp.
Finance expenses were $10.8m, a decrease of $10.3m on the pcp. Included in net finance income/expenses are financing
related foreign exchange gains of $9.3m (pcp $3.5m losses). Discount unwind on earnout and deferred consideration increased
to $17.6m (pcp $15.3m) in the current period.
Page 8
Appendix 4D
Interim Results
Half Year Report
The tax expense of $3.6m comprised:
•
•
•
Current period income tax expense for the six months to 31 December 2024 of $2.4m;
Prior year under provision of $0.1m; and
Expense of $1.1m relating to the movement in net tax deferred tax assets and liabilities.
REVIEW OF STATEMENT OF FINANCIAL POSITION
Cash
Cash decreased by $56.4m compared to 30 June 2024.
Amounts invested in marketable securities (December 2024 $71.2m, June 2024 $39.2m) are not included in cash. Marketable
securities are deposits in a money market fund with underlying investments in short term US government debt and repurchase
obligations. Marketable securities are included in “Other Financial Assets” in the financial statements.
Refer to Review of Cash Flows for further commentary.
Inventory, receivables and trade payables
The Company had a net cash release from working capital of $1.1m during the period. Given the Group experienced increased
revenue, the Company managed the working capital efficiently. Net working capital for continuing operations was stable.
Working capital movements included reductions of inventory ($17.9m), trade receivables ($6.5m) and trade and other payables
($20.2m). The balance sheet and statement of cashflows include values relating to both continuing operations and discontinued
operations. The balance sheet values are also impacted, compared to the pcp, by currency translation with the December 2024
AUD / USD exchange rate of 0.6204 compared to the June 2024 exchange rate of 0.6670.
Intangible assets
Intangible assets increased by $11.6m compared to the balance at 30 June 2024. The movement comprised of:
•
•
•
An increase of $0.8m for asset additions;
A decrease of $28.5m for amortisation; and
An increase of $39.2m due to foreign currency translation with the AUD / USD exchange rate decreasing from 0.6670 at 30
June 2024 to 0.6204 at 31 December 2024. The majority of intangible assets are held in the US.
Property, plant & equipment
Property, plant and equipment increased by $4.7m from the balance at 30 June 2024. The movement comprised of:
•
•
•
An increase of $6.9m for additions which included capital works programs and general site maintenance capital
expenditure;
A decrease of $2.3m for depreciation; and
An increase of $0.1m due to foreign currency translation (almost all property, plant & equipment is held in Australia).
Interest bearing liabilities.
Interest bearing liabilities includes lease liabilities. Lease liabilities were $6.5m at reporting date. Mayne Pharma issued
convertible notes in December 2022 with total cash received of US$27.95m. The convertible notes liability has been split into
two components – the loan liability ($33.4m included in interest bearing liabilities at reporting date) and the conversion option
(derivative) component (initially recognised at $9.7m and subsequently restated at fair value each reporting period – which is
included in the balance sheet as “Other financial liabilities”).
Other financial liabilities
Other financial liabilities increased by $34.5m from 30 June 2024 as a result of:
•
An increase of $17.6m due to the unwinding of the discount for the various earn-out liabilities and deferred consideration
liabilities;
Page 9
Appendix 4D
Interim Results
Half Year Report
•
•
•
•
A decrease of $0.2m due to fair value restatement of the option derivative relating to convertible notes;
A decrease of $1.0m due to re-assessments of various earn-out and deferred consideration liabilities;
A decrease of $10.1m due to payments made for earn-outs and deferred settlements; and
An increase relating to foreign exchange and foreign currency translation of $28.1m.
REVIEW OF CASH FLOWS
Cash at 31 December 2024 was $53.7m, representing a decrease of $56.4m from 30 June 2024. Amounts invested in marketable
securities (December 2024 $71.2m, June 2024 $39.2m) are not included in cash. Marketable securities are deposits in a money
market fund with underlying investments in short term US government debt and repurchase obligations. Marketable securities
are included in “Other Financial Assets” in the financial statements.
A summary of operating cash flows is as follows:
Dec 2024
$M
Dec 2023
$M
Operating cash flow before working capital movements
19.2
(8.9)
Working capital (investment) / release
1.1
(19.8)
Net Operating cash flows before Class Action settlement
20.3
(28.7)
Class Action settlement (net of insurance)
(33.3)
-
Net Operating cash flows
(13.0)
(28.7)
Less estimated cashflows relating to discontinued operations
outflows / (inflows)
5.6
9.5
Estimated net operating cashflows from continuing operations
(7.4)
(19.2)
Operating cash flow was impacted by the Class Action net cash settlement (in July 2024) and discontinued operations including
payments for certain operating expenses and payments for gross-to-net liabilities for the divested Retail Generics business.
Continuing operations working capital efficiency gains enabled stable net working capital even though there was a significant
increase in revenue.
Investing cash flows
Dec 2024
$M
Dec 2023
$M
(45.0)
67.7
Notable cash flows during the period included:
•
•
•
$6.9m payments for net capital expenditure;
$27.2m invested in marketable securities; and
Earn-out and deferred settlement payments totalling $10.1m which included $3.7m paid to Catalent as a result of the MCS
sale.
Financing cash flows
Notable cash flows during the period included:
•
•
Net interest receipts $2.0m; and
Lease payments (right-of-use) assets $2.1m.
DIVIDEND
No dividend was declared or paid for the period ended 31 December 2024.
Page 10
Dec 2024
$M
Dec 2023
$M
(0.3)
(20.2)
Appendix 4D
Interim Results
Half Year Report
ROUNDING
The Company is of a kind referred to in ASIC Legislative Instrument 2016/191 issued by the Australian Securities and
Investments Commission, relating to the “rounding off” of amounts in this report and in the financial report. Amounts in this
report and in the financial report have been rounded off in accordance with that Legislative Instrument to the nearest thousand
dollars or, in certain cases, to the nearest dollar.
AUDITOR’S INDEPENDENCE DECLARATION
The Auditor’s independence declaration is included on page 12 of the Financial Report.
EVENTS SUBSEQUENT TO REPORTING DATE
On 21 February 2025, Mayne Pharma announced it had entered into a Scheme Implementation Deed (’SID’) with Cosette
Pharmaceuticals, Inc. The acquisition price in the SID is $7.40 cash per share and the Mayne Pharma Board has unanimously
recommended that shareholders vote in favour of the Scheme in the absence of a Superior Proposal. The indicative timetable
is included in the ASX announcement dated 21 February 2025.
In relation to NEXTSTELLIS® patents, a new US patent was issued: US Patent No. 12,233,074, claiming certain aspects of
NEXTSTELLIS®, entitled “Contraceptive Methods with Improved Pearl Index”, issued on February 25, 2025 with an expiration
date of February 9, 2043.
No other matter or circumstance has arisen since the reporting date which is not otherwise reflected in this report that
significantly affected or may significantly affect the operations of the Consolidated Entity.
Signed in accordance with a resolution of the Directors.
Dated this 26th day of February 2025.
Frank Condella
Independent Chair
Page 11
Shawn Patrick O’Brien
Managing Director and CEO
Appendix 4D
Interim Results
Half Year Report
AUDITOR’S INDEPENDENCE DECLARATION
Page 12
Appendix 4D
Interim Results
Half Year Report
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE
INCOME
FOR THE HALF-YEAR ENDED 31 DECEMBER 2024
31 December
2024
$’000
31 December
2023
$’000
Continuing operations
Sale of goods
193,722
170,307
Services revenue
18,495
16,886
Royalties revenue
641
516
Notes
License fees
196
217
Revenue
2
213,054
187,926
Cost of sales
2, 3
(82,195)
(82,143)
130,859
105,783
Interest income
2,696
4,064
Other income
1,339
924
Earn-out and deferred consideration liabilities reassessments
1,019
(16,650)
Research, development, medical and regulatory affairs expenses
(9,886)
(10,244)
Marketing and distribution expenses
(65,985)
(65,005)
Gross profit
Administrative and other expenses
3
(63,944)
(72,642)
Finance expenses - other
3
(2,482)
(2,299)
Foreign exchange (losses) / gains related to financing activities
3
9,302
(3,538)
Finance expenses – related to earn-outs & deferred consideration
liabilities including discount unwind
3
(17,637)
(15,258)
(14,719)
(74,865)
Net (loss) / profit before income tax
Income tax credit / (expense)
4
Net (loss) / profit for the period from continuing operations
(5,251)
4,316
(19,970)
(70,549)
(5,575)
(3)
(25,545)
(70,552)
Discontinued operations
Profit after tax for the period from discontinued operations
Net (loss) / profit for the period attributable to equity holders of the
Parent
Page 13
5
Appendix 4D
Interim Results
Half Year Report
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME (continued)
FOR THE HALF-YEAR ENDED 31 DECEMBER 2024
31 December
2024
$’000
31 December
2023
$’000
Exchange differences on translation
18,307
(8,295)
Income tax effect
(2,703)
913
Total comprehensive income for the period
(9,941)
(77,934)
(9,941)
(77,934)
(9,941)
(77,934)
Basic earnings per share
(32.3) cents
(87.8) cents
Diluted earnings per share
(32.3) cents
(87.8) cents
Basic earnings (loss) per share from continuing operations
(25.3) cents
(87.8) cents
Diluted earnings (loss) per share from continuing operations
(25.3) cents
(87.8) cents
Notes
Other comprehensive income for the period, net of tax
Items which may be reclassified to profit/loss
Attributable to:
Equity holders of the Parent
Earnings per share from continuing operations:
This statement should be read in conjunction with the accompanying notes to the financial statements
Page 14
Appendix 4D
Interim Results
Half Year Report
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2024
Notes
31 December 2024
$’000
30 June 2024
$’000
Current assets
Cash and cash equivalents
6
53,710
110,068
Trade and other receivables
7
195,748
193,222
Inventories
8
61,057
74,629
Income tax receivable
15,455
14,455
Other financial assets (includes marketable securities)
73,654
41,530
Other current assets
29,873
26,689
Total current assets
429,497
460,593
16,583
15,337
51,344
46,694
Non-current assets
Other non-current assets
Property, plant and equipment
9
Right-of-use assets
6,155
6,632
Deferred tax assets
4
47,006
45,341
Intangible assets
10
580,150
568,580
701,238
682,584
1,130,735
1,143,177
Total non-current assets
Total assets
Current liabilities
Trade and other payables
11
200,129
244,548
Interest-bearing loans and borrowings
12
37,057
35,461
Other financial liabilities
13
53,557
49,446
Provisions
14
Total current liabilities
15,126
16,124
305,869
345,579
Non-current liabilities
Interest-bearing loans and borrowings
12
2,808
3,359
Other financial liabilities
13
362,773
332,374
Deferred tax liabilities
4
12,696
7,352
Provisions
14
385
325
Total non-current liabilities
378,662
343,410
Total liabilities
684,531
688,989
Net assets
446,204
454,188
1,225,655
1,224,224
Equity
Contributed equity
15
Reserves
190,097
173,967
Accumulated Losses
(969,548)
(944,003)
Total equity
446,204
454,188
This statement should be read in conjunction with the accompanying notes to the financial statements.
Page 15
Appendix 4D
Interim Results
Half Year Report
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE HALF-YEAR ENDED 31 DECEMBER 2024
Contributed
Equity
Share-Based
Payment
Reserve
Foreign
Currency
Translation
Reserve
Other
Reserve
Accumulated
losses
Total Equity
$’000
$’000
$’000
$’000
$’000
$’000
1,224,224
58,584
118,526
(3,143)
(944,003)
454,188
-
-
-
-
(25,545)
(25,545)
Foreign exchange translation (net of tax)
-
-
15,604
-
-
15,604
Total comprehensive income
-
-
15,604
-
(25,545)
(9,941)
Balance at 1 July 2024
Profit / (loss) for the period
Other comprehensive income
Transactions with owners in capacity as
owners
Taxes paid relating to RSU’s vesting
(148)
-
-
-
-
(148)
Equity contribution re LTI program
1,579
(1,579)
-
-
-
-
Share-based payments
-
2,105
-
-
-
2,105
Balance at 31 December 2024
1,225,655
59,110
134,130
(3,143)
(969,548)
446,204
Balance at 1 July 2023
1,233,692
55,957
117,624
(3,143)
(769,770)
634,360
-
-
-
-
(70,552)
(70,552)
Foreign exchange translation (net of tax)
-
-
(7,382)
-
-
(7,382)
Total comprehensive income
-
-
(7,382)
-
(70,552)
(77,934)
(10,932)
-
-
-
-
(10,932)
1,160
(1,160)
-
-
-
-
-
2,279
-
-
-
2,279
1,223,920
57,076
110,242
(3,143)
(840,322)
547,773
Profit / (loss) for the period
Other comprehensive income
Transactions with owners in capacity as
owners
On-market share buy-back
Equity contribution re LTI program
Share-based payments
Balance at 31 December 2023
This statement should be read in conjunction with the accompanying notes to the financial statements.
Page 16
Appendix 4D
Interim Results
Half Year Report
CONSOLIDATED STATEMENT OF CASH FLOW
FOR THE HALF-YEAR ENDED 31 DECEMBER 2024
Notes
31 December
2024
$’000
31 December
2023
$’000
Cash flows from operating activities
Receipts from customers
381,902
374,914
Payments to suppliers and employees
(361,416)
(403,597)
(216)
(38)
Net cash flows from operating activities before Class Action settlement
20,270
(28,721)
Class Action settlement (net of insurance)
(33,300)
-
(13,030)
(28,721)
Tax paid
Net cash flows from operating activities
6
Cash flows from investing activities
Payments for plant and equipment
(6,872)
(3,174)
Redemption of marketable securities
-
91,628
Investment in marketable securities
(27,215)
-
(831)
(13,020)
Earn-out and deferred settlement payments
(10,076)
(8,227)
Net cash flows used in investing activities
(44,994)
67,207
-
(10,990)
(742)
(537)
Payments for intangible assets
Cash flows from financing activities
Repayment of borrowings (receivables finance facility)
Payments of interest
Receipts of interest
2,696
4,064
Payment of lease liabilities (right-of-use assets)
(2,066)
(1,806)
Taxes paid relating to RSU’s vesting
(148)
-
-
(10,932)
(260)
(20,201)
Net increase/(decrease) in cash and cash equivalents
(58,284)
18,285
Cash and cash equivalents at beginning of period
110,068
92,616
On market share buy-back
Net cash flows from financing activities
Effect of foreign exchange changes on cash held in foreign currencies
Cash and cash equivalents at end of peri
Share your feedback
Discover